|
### Co enzyme Q 10 CURE for CANCER:
CoQ10 Facts
1. Coenzyme Q10 is an essential biomolecule that functions in the production of biochemical energy in aerobic organisms.
2. Coenzyme Q10 is an essential electron and proton carrier.
3. Coenzyme Q10 has properties that stabilize membranes.
4. Coenzyme Q10 also contains antioxidant that prevents damage to cells due to normal metabolic processes.
5. Coenzyme Q10 is made up of carbon, hydrogen and oxygen and its formula is C59H90O4.
6. Coenzyme Q10 consists of quinone ring attached to an isoprene side chain.
7. All mammalian tissues produce Coenzyme Q10.
## COQ10 FOR CANCER... from http://www.cancer.gov/cancerinfo/pdq/cam/coenzymeQ10
## Ubiquinone CQ10 (coenzyme Q10) and Cancer...from http://www.newmediaexplorer.org/chris/2003/07/31/cq10_coenzyme_q10_and_cancer.htm
COQ10 BASICS
Coenzyme Q10 is a vitamin-like fat-soluble antioxidant found everywhere in the body; the highest concentrations have been measured in vital organs such as the heart and pancreas. At age 20, the heart has a higher CoQ10 level than other major organs. At age 80 this is no longer true, with the heart levels cut by more than half. More than 35 controlled clinical trials in Japan, Europe and the U.S. have proven that CoQ10 therapy is highly effective in treatment of congestive heart failure, angina and ischemic heart disease, and myocardial infarction.
It is now believed that CoQ10 is the key nutrient for generating 95 percent of the total energy required by the human body.
A healthy, youthful human body can make its own CoQ10. Endogenous production or biosynthesis of CoQ10 has 17 steps, requiring at least seven vitamins (vitamin B2 - riboflavin, vitamin B3 - niacinamide, vitamin B6, folic acid, vitamin B12, vitamin C, and pantothenic acid) and several trace elements.
The pharmaceutical giant Merck has known for more than 15 years that statin drugs interfere with CoQ10 biosynthesis; leading to low serum levels which cause muscles to atrophy. The following claim from one of two 1990 Merck patents (4,933,165) is to add CoQ10 to statin drugs in order to overcome statin induced myopathy:
1. A pharmaceutical composition comprising a pharmaceutical carrier and an effective antihypercholesterolemic amount of an HMG-CoA reductase inhibitor and an amount of Coenzyme Q.sub.10 effective to counteract HMG-CoA reductase inhibitor-associated skeletal muscle myopathy.
This invention has never been implemented, probably because the entire world supply of CoQ10 is limited and current production would only supply one-sixth of the world's statin users.
VARIOUS HEALTH BENEFITS ATTRIBUTED TO COQ10
The CoQ10 science has accelerated from its discovery in 1957 until the present day and appears excellent. [*] The following headlines summarize the many clinical studies that have shown CoQ10 supplementation beneficial in disease conditions ranging from Parkinson's disease to cataracts. Dosages studied range from 30 mg to 1200 mg daily. Higher dosages have generally been found to be more beneficial.
- CoQ10 gives complete protection against stroke
Since 1972, in studies of stroke in three animal models (dog, rat, gerbil) ubiquinone (coq10) was the only agent giving complete protection and this was over two times more often than the next best agent (naloxone) of the many tested to date. [*]
- CoQ10 benefits Cardiovascular Disease
CoQ10 levels in heart tissue decline disproportionately with age. CoQ10 pioneer Karl Folkers (1985), in agreement with earlier Japanese studies, found lower CoQ10 levels in patients with more severe heart disease and showed that CoQ10 supplements significantly raised blood and heart tissue levels of CoQ10 in these patients. [*]
- CoQ10 improves high blood pressure
" At least six clinical trials have shown a blood pressure-lowering effect of CoQ10. [*]
- CoQ10 for Parkinson's disease.
"Less disability developed in subjects on CoQ10 than in those on placebo, and the benefit was greatest in people receiving the highest dosage." [*]
- CoQ10 benefits people with kidney failure.
" Because CoQ10 has the potential to revolutionize the treatment of chronic renal failure, a large-scale, long-term study should be initiated as soon as possible." - Alan Gaby [*]
- CoQ10 for youthful skin
" Just recently scientists have also discovered that this natural supplement may even slow down the skin's aging process. Gerson Unna confirmed that, like vitamin E, Co-Q10 slows down tissue damage by decreasing the effect of free radical molecules. In a placebo-controlled study, researchers at Beiersdorf discovered that after six weeks of daily treatment on crow's feet (eye wrinkles), wrinkle depth was reduced by 27 percent; after 10 weeks, fine lines and wrinkles were reduced by a surprising 43 percent. The enzyme also has been effective in the reduction and fading of age spots and is touted by Beiersdorf for its lack of toxicity. [*]
- CoQ10 Effective for Migraine Prevention [*]
- CoQ10 Therapy can improve glucose control in Type 2 diabetics [*]
- 400 mg CoQ10 reportedly induced cancer remissions. [*]
Science has uncovered even more benefits of supplemental CoQ10. [*]
COQ10 SUPPLEMENTATION IS NECESSARY AS WE AGE
Researcher Dr. John Ely, of the University of Washington, holds that CoQ10 supplementation is essential in the aged. Most people make approximately 500 mg of Coq10 daily in the body, at least up until age 21. Between ages 21 and 30, levels of CoQ10 begin to drop, perhaps because of aging. This causes the degeneration of cells, which may contribute to age-related diseases and conditions such as high blood pressure, arthritis, heart disease and the breakdown of skin tissue.
Statin drugs and deficiencies in several other vitamins also cause blood levels of CoQ10 to drop.
According to Dr. Ely,
"Possibly the most important details not reported previously are those related to CoQ10 body pool and turnover rate that mandate human supplementation. Adult human body pool has been found to be approximately 2 grams and requires replacement of about 0.5 grams/day based on its average turnover rate of about 4 days in various tissues. This must be supplied either by endogenous synthesis or from exogenous sources. Synthesis decreases progressively in humans above age 21. Furthermore, the average ubiquinone content of the western diet is less than 5 mg/day. Thus, ubiquinone supplementation appears to be the only way for older people, and certainly the ill, to obtain the major proportion of the 0.5 gram/day need. Failure to supplement by the aged, ill or stressed, can have tragic consequences in the form of irreversible damage in the brain, other organs and mitochondria everywhere." [ http://faculty.washington.edu/ely/turnover.htm ].
CoQ10 pioneer Karl Folkers claimed that the primary source of CoQ10 in man is biosynthesis. Folkers argues that" suboptimal nutrient intake in man is almost universal causing subsequent secondary impairment in CoQ10 biosynthesis." According to CoQ10 expert Peter H. Langsjoen, MD. "This means that average or "normal" levels of CoQ10 are really suboptimal and the very low levels observed in advanced disease states represent only the tip of a deficiency ice berg."
The Vitamin C Connection
Vitamin C is a "natural" HMG-CoA reductase inhibitor. [*] It was observed experimentally that when vitamin C levels are low, cholesterol becomes elevated, and when more vitamin C is consumed, cholesterol levels decline. The mechanism by which vitamin C lowers cholesterol was discovered circa 1985. High Vitamin C levels inhibit the same the HMG-CoA Reductase enzyme as the statin drugs. The inescapable conclusion is that vitamin C does what statins do - lowers cholesterol -- without side-effects. If the statin drugs were patterned after Vitamin C, they lack many other benefits of the vitamin. For example, vitamin C promotes the production of coenzyme Q10 and lowers Lp(a).
It is interesting that in addition to vitamin C, our bodies require many B vitamins to synthesize CoQ10. Voluminous research has found beneficial effects from ascorbic acid supplementation similar to the effects found from smaller dose CoQ10 supplementation. For example, in a recent study, hydro soluble CoQ10 supplementation was shown to lower circulating levels of Lp(a). We speculate that some of these similar effects may be due to increased endogenous CoQ10 synthesis induced by the ascorbic acid along with generally better all around nutrition.
Every human body makes up to 500 mg of CoQ10 daily; no human body can make vitamin C. As important as CoQ10 is for health, vitamin C is more important, perhaps an order of magnitude. That fact is that most mammals synthesize ten times more vitamin C than they do CoQ10, when adjusted for body weight. Under normal circumstances the daily amount of ascorbic acid produced by mammals lies between 3,000 mg and 15,000 mg, with an average of 5,400 mg, when adjusted for comparison to the weight of the average male human being.
We conclude that everyone should supplement 3,000 mg to 6,000mg vitamin C daily from birth, including during pregnancy. On the other hand, healthy, well-nourished children will usually synthesize their own CoQ10. With the possible exception of athletes, persons taking vitamin C should not have to supplement CoQ10 until the fourth or fifth decade of life. Athletes have a high requirement for CoQ10 and may benefit from supplementation earlier in life.
According Dr. Langsjoen, "The resulting lowering of blood CoQ10 level is due to the partially shared biosynthetic pathway of CoQ10 and cholesterol. In patients with heart failure this is more than a laboratory observation. It has a significant harmful effect which can be negated by oral CoQ10 supplementation."
to the top
### Vitamin B 17 to cure Cancer: ( Amygdalin or Nitrilosides )
Contains a cyanide ingredient that is harmful to cancer cells. It is most effective for preventing cancer if taken regularly by eating a few bitter seeds of stone fruits or pip fruits (for example, apricot, bitter almond, apple). Other good sources are sprouted seeds, alfalfa, mung beans, millet, lentils. Professionally, a purified product, known as laetrile, is wed orally or as injections for cancer treatment. To be effective, laetrile must be used in conjunction with cleansing, supplements and correct diet.
## from http://db.ancient-future.net/vitamins.html
Vitamin B17*: http://www.metabolicproductssupply.com/cat1_1.htm
Chemical Names - Amygdalin, Prunasin (d-mandelonitrile glucoside), Dhurrin, Linamarin, Lotaustralin, Sambunigrin (l-mandelonitrile glucoside), Prulaurasin (dl-mandelonitrile glucoside), Triglochinin, Linustatin, Neolinustatin.
Deficiency- Possibly increased incidence of cancer, Optimal intake- 25-100 mg
Good Sources - Apricot seeds, buckwheat, millet, lima beans, flax
Discussion- Also known as laetrile, anti-cancer substance. B17 is a group of cyanide producing sugars known as "cyanogenic glycosides," that release cyanide when acted upon by the enzyme beta-glucosidase. Often taken in concentrated form of amygdalin, but soon after mixed with water, the chemical is subject to ephemerization, so quality is poor when pre-mixed in water. Rodent research suggests anti-metastatic effect at high injectable doses. Vitamin status unlikely.
## http://www.luminet.net/~wenonah/history/griffin.htm
LECTURE BY MR. G. EDWARD GRIFFIN
Author of "World Without Cancer: The Story of Vitamin B-17"
Cancer is not going to cause just one premature death. It is going to account for one out of every four of us here this evening, …
… The Committee for Freedom of Choice in Cancer Therapy believes that a material which has been widely tested shows great promise as a major weapon against cancer….I am speaking, of course, of Laetrile, also known as Amygdalin or Vitamin B-17. But this Committee was formed because, as the title suggests, we are being denied freedom of choice in testing and developing the full potential of laetrile which experience suggests, …
… The first time I was introduced to the subject of Laetrile or vitamin therapy in the control of cancer, was when I was on a short fishing trip with Dr. John Richardson, a physician in San Francisco, who as you probably know, is in the forefront of the legal battle to establish the physician's right to use laetrile or vitamin therapy or anything he wishes to use, in the treatment of his patients. Because he was using laetrile last year he was arrested by the FDA, and he is taking this case to the courts. …
… Finally he began to tell me about the fact that "they" were suppressing this. "They" wouldn't let him use it, "they" were harassing him. I thought all of a sudden, good grief, John. Why he is becoming paranoid and I turned to him, and I remember very distinctly, I said, "Wait a minute, who are "they" John? Do you mean to tell me that there are people in the medical profession or in government or anywhere in the world who are so low and so crass, so mean, as to deliberately withhold a control for cancer?" And I didn't realize it at the time, but with the asking of that question my curiosity was already aroused and I was launched even then on an investigative research project that was to take me two or two and a half years, and it led me to the discovery of one of the most amazing stories of the twentieth century.
… This evening I am forced, because of the limitation of time, to assume that you are familiar with the science of Vitamin B-17 or laetrile. …
… Our research has led us to the realization that cancer is simply a deficiency disease, like scurvy, pellagra and pernicious anemia. It is caused by the lack of an essential food compound in modern man's diet. It is not caused by a virus or some mysterious toxin. It is caused by the lack of something. And the ultimate solution for the control of cancer, therefore, simply is to restore this essential food element to our daily intake…
[ This lack of proper nutrients, which are responsible for maintaining our natural immune system, or other sources of stress, activates a "Pleomorphic" virus that has been proven conclusively to bring about most cancerous conditions - Tommy Cichanowski ]
…It is known as Amygdalin when it is found in nature. As such, under the name of Amygdalin, it has been listed in the Standard Pharmathera for over a hundred years. It is identified and known for all this time, listed as a non-toxic. It has been used experimentally on a wide variety of ailments in every country of the world. It is particularly well known in Asia, but also definitely known in the United States and Europe. When it is described by nutritionists, it usually is referred to as nitrolosides. In its purified and concentrated form used specifically for cancer therapy, the form developed by Dr. Ernest T. Crebb, Jr., it is known as Laetrile.
I think the best way to describe this substance is simply to call it what it really is. It is a vitamin and it is vitamin B-17. That is how it will be known in the future - Vitamin B-17, because it is found in that grouping of vitamins known as the B-complex, of which there are some twenty-four fractions. It is found in that grouping of vitamins when it is found in natural foods. And since it was the seventh one to be isolated and identified, it is properly known as Vitamin B-17, and one last thing, just to give you a little more information about it, it is found in over 1,2000 edible plants around the world, most of which you wouldn't dream of eating: grasses, Johnson grass, Tunis grass, arrow grass, and things like that.
It is also found in the foods of primitive man, primitive cultures which even today are noted for their lack of cancer. There are many cultures in the world including the Akkadians(?) on the Black Sea, the Hunzakut of Northwest Pakistan, the Hopi and Navaho Native Americans, the traditional Eskimo, and groups like this in Africa, Latin America and all around the world which traditionally are cancer free, or relatively cancer free. And in every case, ladies and gentlemen, when you examine the natural diets of these cancer free populations you always find that the degree to which they are free of cancer is the same degree to which their foods are rich in vitamin B-17. There are no exceptions to that statement.
… Let's begin then with reality number one. The scientific basis for the opposition against laetrile or vitamin B-17 has been blatantly dishonest. Not one physician out of a thousand has ever had a chance to use laetrile or vitamin B-17 himself. And yet, most physicians, if you ask them if laetrile works, they will say no, it does not. … They are, almost all of them, referring to an original research project that was conducted in the State of California in 1953. It is known as the California Report and it was published by the Cancer Advisory Commission of the California Medical Association.
So, now let's take a look at the California Report since this is the mainspring of 99% of the scientific and legal opposition to laetrile today… It was written by two men, Dr. E. M. McDonald the Committee Chairman, and Dr. Henry Garland, the Committee Secretary… None of these men, ladies and gentlemen, including McDonald and Garland has ever used laetrile. All they had done was to summarize and interpret the written records of medical people who had done various phases, different kinds of experimentation of laetrile. They read these reports submitted to them, and then summarized them and issued their own report, which was to tell us what they found.
… Well, you may not remember them by name, but McDonald and Garland were the two physicians who at that time were making headlines all across the country by claiming publicly and vociferously that there was absolutely no connection between cigarette smoking in particular and lung cancer. …
… Now, as an interesting sidelight to all of this, Dr. McDonald died a few years later. He was incinerated in a fire started by his cigarette while he was asleep. Dr. Garland who had boasted that he was living proof that smoking was safe because he had been a chain smoker ever since he was a boy, he said, "Here I am, perfectly healthy, that's proof that you don't have to worry about smoking." He, of course died of lung cancer.
Now, but more important than this, ladies and gentlemen, is that McDonald and Garland, more important than their scientific ineptitude, is that they falsified their summary of the laetrile experiments … The reason I can say that is because ten years later, almost by a fluke, the original documents that McDonald and Garland used to analyze and upon which they based their summary were published and made part of the public record.
… In 1963, the State of California Department of Public Health revised its original California Report, updated it, added a few more things to it and reprinted the whole thing, including those original studies in this book entitled, "Report by Cancer Advisory Council on Treatment of Cancer with Beta-cyanogenic Glucosides" or laetrile, and low and behold, when you go to the appendix and look at those old ten year old reports you find that McDonald and Garland had lied. … cyanide is an essential part of the anti-cancer action of laetrile or vitamin B-17. … Indeed, when taken in the gaseous form and when taken to excessive quantities, but cyanide in trace amounts as you will see, when you get into the scientific question in trace amounts, is not only safe but very essential for health.
In fact, many doctors have not thought about the fact that cyanocobaltin [ vitamin B-12 ] has a cyanide radical in the molecule. Also, the fact that cyanide is in the vitamin B-17 is about the same as saying well golly, we dare not eat any table salt because table salt is sodium chloride and you all know that chlorine gas is deadly. All right vitamin B-17 is hydrocyanic acid. …
… Today it is common to use as much as two or three grams of Vitamin B-17 in a single injection and generally it takes somewhere between 30 and 40 grams total over the course of a week to ten days before the average cancer patient is able to report tangible signs of progress. Thirty to forty grams total.
… Some of these studies admitted openly that there was anticancer activity but they've all attributed it to other causes. They said well, since the theory is wrong with laetrile, we know that it can't be the laetrile doing these things, so it must have been a spontaneous remission or the delayed benefits radiation or something like that…
… This is the January 10, 1974 copy of the Los Angeles Times. There was an article there heading "A Controversial Drug", and in it said Dr. Robert A. Goode, President and Director of the Sloan-Kettering Institute of Cancer Research, "at this moment there is no evidence that laetrile has any affect on cancer." That's two months after their report at Baden-Baden, Germany. Two months after they announced to the world, to all the experts in the world that laetrile was effective. Now two months later, they reversed their position and said, "At this moment there is no evidence that laetrile has any affect on cancer." …
to the top
### DiChloroAcetate ( DCA ) vs. Cancer: from http://rexresearch.com/diclacet/dca.htm
A Cheap and Simple Cure for Cancer? by Andy Coghlan ; New Scientist ( Wednesday, January 17, 2007 ) ---
New Scientist has received an unprecedented amount of interest in this story from readers. If you would like up-to-date information on any plans for clinical trials of DCA in patients with cancer, or would like to donate towards a fund for such trials, please visit the site set up by the University of Alberta and the Alberta Cancer Board ( ). We will also follow events closely and will report any progress as it happens.
It is rare to find a drug that sweeps away decades of assumptions and reveals a radical approach to treating all forms of a disease. But a simple, small molecule called dichloroacetate (DCA) has done just that - and to that most dreaded of diseases: cancer.
The new findings ( http://www.newscientist.com/article/dn10971-cheap-safe-drug-kills-most-cancers.html ) might also force a rethink on what actually causes cells to turn cancerous in the first place. In 1930, biochemist Otto Warburg, proposed that cells turn cancerous through a fundamental change in the way they generate their energy. Normally, cells use specialised organelles called mitochondria to supply their energy. Cancer cells shift to a process called glycolysis which takes place in the main body of the cell. Glycolysis is an inefficient system of making energy which normal cells employ only when oxygen is in short supply, switching to mitochondrial energy production when oxygen levels increase.
Curiously, Warburg discovered that cancer cells continue to use glycolysis even when oxygen is plentiful. He called this the “Warburg effect”, and claimed it was common to all cancer cells. His ideas were dismissed and buried long ago, not least when another famous biochemist, Hans Krebs, said the Warburg effect was a symptom of cancer, not the primary cause. This scepticism was reinforced by the belief that cancer cells switch to glycolysis because their mitochondria are damaged and don’t work any more. Enter DCA, which has been used for years to treat people with mitochondrial disease. The drug boosts the ability of mitochondria to generate energy. When given to cancer cells it did the same: the cells switched from glycolysis to mitochondrial energy production. What's more, functional mitochondria help cells recognise functional abnormalities and trigger cell death.
In tests, the DCA caused cancer cells to lose their “immortality” and die. When the drug was given to rats with human tumours, the tumours shrank. Warburg may have been right after all - glycolysis may be more than just a symptom of cancer. So why not rush straight into clinical trials with this drug? It is cheap, does not appear to affect normal cells, we know its side effects, and it should work on all cancers. There's a hitch: dichloroacetate is an old drug and so cannot be patented. The upshot is that pharmaceutical companies can’t stop rivals making and selling it more cheaply, so it’s not worth their while to go to the huge expense of testing it in clinical trials. This is not a new problem. Many drugs are left on the shelf because companies cannot make lots of money from them. It has happened for diseases that affect mainly poor people, such as TB, although there are now an increasing number of initiatives to help deal with these cases. But cancer is historically a disease that chiefly afflicts the rich, and testing DCA will need a one-off effort. Drugs companies will be falling over themselves to find a patentable drug with similar action to DCA. Any of these that reach the market will be hugely expensive. It would be a scandal if a cheap alternative with such astonishing potential were not given a chance simply because it won't turn a big enough profit.
to the top
# Mitochondria Activation Reduces Cancer, (January 21, 2007) http://www.futurepundit.com/archives/004028.html
A small molecule activates suppressed mitochondria in cancer cells and the cells start acting normal.
January 16, 2007 - Edmonton - DCA is an odourless, colourless, inexpensive, relatively non-toxic, small molecule. And researchers at the University of Alberta believe it may soon be used as an effective treatment for many forms of cancer. One qualifier to the above statement: Whether dichloroacetate (DCA) would really be non-toxic when used in therapeutic doses against cancer remains to be seen. When used to treat a genetic disorder involving high lactic acid DCA caused peripheral neuropathy. DCA inhibits a kinase enzyme that deactivates an enzyme called pyruvate dehydrogenase (PDH) which is involved in mitochondrial metabolism (i.e, it is involved in sugar breakdown to make energy).
Dr. Evangelos Michelakis, a professor at the U of A Department of Medicine, has shown that dichloroacetate (DCA) causes regression in several cancers, including lung, breast and brain tumors. Michelakis and his colleagues, including post-doctoral fellow Dr. Sebastian Bonnet, have published the results of their research in the journal Cancer Cell. Many cancer cells do not break sugar down completely. They just do a step called glycolysis. They do not do a step called the Krebs cycle (aka the citric acid cycle or tricarboxylic acid cycle or TCA cycle) which extracts all the energy out of sugar molecules to make energy carrier molecules called NADH and ATP. This was first observed about cancer all the way back in the 1930s. Up until now the assumption to explain this was that cancer cells lost that ability. But this result suggests that not only do cancer cells suppress that ability but that suppression helps them grow uncontrollably.
Pyruvate dehydrogenase (PDH) synthesizes acetyl-CoA which is used in the first step of the TCA cycle in mitochondria. If DCA has either toxicity problems or problems with achieving sufficient doses that does not defeat this approach to anti-cancer drug development. The kinase that DCA blocks could become a target for drug development. A drug that would disable that kinase would likely activate mitochondria in cancer cells just like DCA does. I remember a scientist telling me decades ago that classic intermediary metabolism doesn't get the attention it deserves because everyone was rushing into genetics. Many scientists decided that there was little of interest left to learn from studying the main pathways of energy metabolism. This result argues for his view. How can we get all the way to the year 2007 without noticing sooner the powerful results from a simple long known molecule? Michelakis decided the conventional wisdom on cancer and mitochondria might be wrong and decided to test it.
Until recently, researchers believed that cancer-affected mitochondria are permanently damaged and that this damage is the result, not the cause, of the cancer. But Michelakis, a cardiologist, questioned this belief and began testing DCA, which activates a critical mitochondrial enzyme, as a way to "revive" cancer-affected mitochondria. The results astounded him.
Michelakis and his colleagues found that DCA normalized the mitochondrial function in many cancers, showing that their function was actively suppressed by the cancer but was not permanently damaged by it. More importantly, they found that the normalization of mitochondrial function resulted in a significant decrease in tumor growth both in test tubes and in animal models. Also, they noted that DCA, unlike most currently used chemotherapies, did not have any effects on normal, non-cancerous tissues. No one single molecule is going to cure all cancers by itself. But combinations of compounds that each toxicity highly specific to cancer cells will certainly end up curing a great many cancers. Monoclonal antibodies targetted at cancers, anti-angiogenesis compounds that block blood vessel growth in cancers, gene therapies that activate in cancer cells and assorted other compounds such as DCA are going to cure many cancers when used in combination.
"I think DCA can be selective for cancer because it attacks a fundamental process in cancer development that is unique to cancer cells," Michelakis said. "Cancer cells actively suppress their mitochondria, which alters their metabolism, and this appears to offer cancer cells a significant advantage in growth compared to normal cells, as well as protection from many standard chemotherapies. Because mitochondria regulate cell death - or apoptosis - cancer cells can thus achieve resistance to apoptosis, and this appears to be reversed by DCA." The suppression of mitochondria might be a way for cancer cells to divide in low oxygen environments found deep in tumors lacking in sufficient vasculature. By turning on mitochondria in these cells their need for oygen is probably increased and that likely contributes to their death. This suggests that DCA might work well in combination with anti-angiogenesis drugs since the ability of anti-angiogenesis drugs to block blood vessel growth will decrease the amount of oxygen available to tumors and therefore make more cells in tumors susceptible to the effects of DCA.
DCA (aka Ceresine) has a big problem: It is not patentable and hence provides little incentive for commercial companies to raise money to fund clinical studies to develop it as an anti-cancer drug. People who are philosophically opposed to patents ought to take note of this. Furthermore, the DCA compound is not patented or owned by any pharmaceutical company, and, therefore, would likely be an inexpensive drug to administer, Michelakis added. However, as DCA is not patented, Michelakis is concerned that it may be difficult to find funding from private investors to test DCA in clinical trials. He is grateful for the support he has already received from publicly funded agencies, such as the Canadian Institutes for Health Research (CIHR), and he is hopeful such support will continue and allow him to conduct clinical trials of DCA on cancer patients.
If DCA is on the market in less regulated countries then maybe it'll get tried out in human cancer patients under less restrictive regulatory regimes. DCA hasn't been tried yet in humans against cancer.
Evangelos Michelakis of the University of Alberta in Edmonton, Canada, and his colleagues tested DCA on human cells cultured outside the body and found that it killed lung, breast and brain cancer cells, but not healthy cells. Tumours in rats deliberately infected with human cancer also shrank drastically when they were fed DCA-laced water for several weeks. People who have fatal diseases should be allowed to try anything as a treatment.
to the top
# WO 2006108276 ; A METHOD OF TREATING CANCER USING DICHLOROACETATE ; ( 10-19-2006 )
[ Complete Patent, PDF Format http://rexresearch.com/diclacet/wo06108276.pdf ]
MICHELAKIS EVANGELOS (CA); ARCHER STEPHEN (CA) ; Applicant: UNIV ALBERTA (CA); MICHELAKIS EVANGELOS (CA); ARCHER STEPHEN (CA)
Classification: - international: A61K31/19; A61P35/00; C12Q1/00; A61K31/185; A61P35/00; C12Q1/00; - European: G01N33/50D2B ; Application number: WO2006CA00548 20060411 ; Priority number(s): US20050669884P 20050411
to the top
### Dr. Alexander Ferenczi, Red Beet to cure Cancer:
January 3, 1994, Beet Therapy for Cancer , BEETS.ASC, This file shared with KeelyNet courtesy of John Draper.
One of the most remarkable and tremendously successful programs for treating many different kinds of cancer tumors was commenced in the late 1950's by Alexander Ferenczi, MD., at the Department for Internal Diseases at the district hospital at Csoma, Hungary, using nothing but raw, red beets.
Portions of his intriguing medical success were translated from Hungarian and reprinted in the Australian International Clinical Nutrition Review for July 1986.
Dr. Ferenczi's clinical report included methods of administering the beets and several very important case studies;
# In D. S., a man of 50 years of age, a lung tumor was diagnosed by me and subsequently confirmed in a Budapest hospital, which corresponded clinically to lung cancer....I started the treatment with beetroot in the described manner.
After 6 weeks of treatment the tumor had disappeared...After 4 months of treatment he gained 10kg. (22lbs.) in weight, the erythrocyte (mature red blood cell) sediment rate (e.s.r.) was reduced from 87 millimeters/h to 77mm/h. Thus, he represented the symptoms of a clinical recovery.
# A side-by-side comparison of two cancer patients, one on beet therapy and the other not, further demonstrates the efficacy of this marvelous treatment.
We received simultaneously two patients for treatment. One suffered from cancer of the prostate and the other from cancer of the uterus. The body weight of both was the same.
The patient with cancer of the prostate was treated with beetroot. The patient with cancer of the uterus could not take it, but remained in our ward. The condition of the man started to improve.
When admitted, he was bedridden with a permanent catheter. After one month, the catheter was removed. The patient walked around and put on weight, whereas the female patient lost weight. After 3 months, there was a difference in weight of 10.5kg (23.15lbs.) between the two.
Experience gained up to now points to the fact the beetroot contains a tumor inhibiting (anti-cancerous) active ingredient. However, for the present no clue has been found as to the nature of this active substance. One thing is certain, that it is not very unstable because it also acts when taken orally; therefore digestion does not harm it.
The very apparent red color may suggest that the active substance is the coloring matter.
Treatment with beetroot presents several advantages over cancer.
Firstly, because it is non-toxic and one can administer red beetroot in unlimited quantities. Also there are unlimited supplies of beetroot at our disposal.
We have therefore endeavored to administer to the patient this active substance in the most concentrated form and in the largest quantities possible, because the beetroot or rather the JUICE could not be given in large quantities.
Beetroot is available to consumers in several different forms. One Lawrence, Kansas firm, PINES INTERNATIONAL, makes a very nice organic red beet root concentrate. This beet powder is available at most local health food stores.
One, however, has to be careful with the amount of beets consumed at any one time. Certainly not because they're harmful, but rather due to their incredibly strong ability to quickly break up cancer in the body.
# A woman in her thirties who was treated with beetroot for breast cancer, contracted a fever of 104 degrees F., due to the rapid breakdown of the wastes dumped into it at any one time.
Consequently, the internal administration of beetroot needs to be staggered out somewhat, and closer attention given to DETOXIFYING the liver and colon at the same time the beetroot therapy is commenced.
Dr. Ferenczi concluded his medical report with this undeniable fact:
"The results achieved with beetroot are no worse than those with well-known chemical preparations, such as those with Tetramin (an experimental anti-neoplastic)."
He attributed the anti-cancer strength in beets to their natural red coloring agent, BETAINE.
to the top
### KOMBUCHA against cancer: http://www.kalamark.com/batyah/essiac.html
Ten years later, Dr. Rudolf Sklenar of Oberhessen reported in the periodical "Experiential Healing Science" about his various techniques of diagnosis and therapy.
The tea fungus is mentioned as an outstanding remedy which he considered to be a powerful agent for detoxifying the human body since it dissolves micro-organisms and also cholesterol. Some of his specific cancer treatments were based on the use of fermented tea for the balancing of intestinal flora.
With the tea fungus he successfully treated gout, rheumatic conditions, arteriosclerosis, arthritis, dysbacteria, constipation, impotence, non-specific draining, obesity, furunculosis, kidney stones, cholesterol and finally cancer in the early stages of detection.
In 1987, Dr. Veronika Carstens, recommends Kombucha in a series called "Help from Nature - My Remedies Against Cancer" with the words:
"Kombucha detoxifies the organism and enhances the metabolism; this improves the defense capacity."
In the Netherlands, A J Lodesijkx of Ermelo - a natural healing specialist - describes the health-giving benefits of the fungus in his book "Life Without Cancer". He concludes that the Kombucha fungus has strongly antiseptic properties. It purifies the glandular system and promotes the elimination and neutralisation of uric acid.
He concludes that the fermented beverage is an excellent remedy for gout, rheuma, arthritis, kidney stones, intestinal dysbacteria and early stages of cancer due to its influence on disease causing endobionts. (Red corpuscles are eliminated by these endobionts when the pH of the blood shifts unfavorably to the alkaline side.)
Kombucha is considered to be unique in that it actively re-balances the blood pH and thus helps to counter any disease processes that are in operation.
to the top
## Glivec help against Leukaemia (CML) http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2006/06/06/ncanc06.xml
One pill a day keeps cancer at bay. By Celia Hall, Medical Editor (Filed: 06/06/2006)
A drug prescribed for one of the commonest forms of leukaemia has reduced the deadly cancer to a chronic illness that can be managed with a single pill a day, specialists said yesterday.
New data issued in London showed that about 90 per cent of patients with chronic myeloid leukaemia (CML) who take the drug Glivec are alive and well after five years.
Before the drug was developed, the blood cancer would become advanced within four to six years, giving little hope of survival.
Specialists described the results as "breathtaking". They said that, unlike some cancer drugs which had shown early promise that then faded, Glivec patients had an "impressively durable resp-onse to the drug".
CML is one of the four most common types of leukaemia. It is a blood cancer in which the white blood cells do not mature and are over-produced.
The condition can lead to tumours forming on the bone marrow or lymph nodes and can also increase the risk of strokes and life-threatening infections.
Patients take the drug for life. In some it is weeks before real benefits can be measured but other patients report feeling better within a few days. While the drug does not cure the leukaemia, it keeps it under control.
Before Glivec, patients with CML had a life expectancy of four to six years. In the long-term trial only 4.6 per cent of patients died. The drug costs the health service from £14,000 a year per patient, depending on the strength of the dose, and is recommended for those for whom a bone marrow transplant is not an option.
Pennie Douglas, of CML Support, said her organisation was worried that not all patients had swift access to the drug or that they remained on it. "We are concerned about people who are not treated at the specialist centres. There are misunderstandings at some hospital departments. "We have heard that some patients whose test results are good are taken off it. It is a funding issues for many primary care trusts."
About 3,000 people in the country have CML and about 600 a year are newly diagnosed. It usually strikes in middle age.
Glivec is also having good results with a rare cancer of the digestive tract known as gist and is being tried with other cancers, including some that attack the prostate, lungs and brain. Glivec is designed to stop the cancer cells from multiplying. It works by blocking or inhibiting signals that instruct the cancers cells to divide and grow. Sufferers normally take one tablet a day for as long as it is shown that they continue to benefit from it.
Users of the drug have reported some mild side-effects, including nausea and sometimes diarrhoea. It can also cause leg aches and cramp, rashes and swelling of the face, especially around the eyes. Such side-effects are usually treatable.
Charles Craddock, professor of haematology at Birmingham University and the director of the stem cell transplant unit at the city's Queen Elizabeth Hospital, said that results from earlier drug treatments for CML had been "pretty gloomy". "I am delighted that the remarkable results we initially saw in CML patients treated with Glivec five years ago have continued to improve. "The significant success of Glivec in treating CML is an exciting model for the development of new treatments for other cancers."
Dave Cook, a spokesman, said: "The data that we have seen confirm what I have experienced for myself. When six separate gists were removed, I was devastated but after four years on Glivec my scans show no signs of any abnormality. Glivec is a life-saver."
Sandy Craine, 58, from Liverpool, was one of the first people in Britain to take Glivec and formed a support group. She said: "When it became available five years ago I never believed that I would be standing here today. "I was told that without invasive chemotherapy following a stem cell transplant I had approximately 12 months to live. "It has helped save to my life and I am so grateful that I can pass on this message of hope to others diagnosed with this once devastating disease."
Publishers wishing to reproduce photographs on this page should phone 44 (0) 207 538 7505 or e-mail syndication@telegraph.co.uk
to the top
to the top
|
Parcourez les archives de Tesla3.com en 7 catégories:
Find the older websites here >> http://waterfuel.100free.com and http://waterfuel.t35.com << Trouvez les anciens websites ici 